LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company

Core Viewpoint - LakeShore Biopharma has received a revised preliminary non-binding proposal from Oceanpine Skyline Inc. to acquire all outstanding ordinary shares of the company at a reduced price of US$0.06 per share, which represents a 50% premium over the last trading price on March 20, 2026 [1][11]. Group 1: Proposal Details - The revised proposal aims to acquire all ordinary shares not owned by Oceanpine or its affiliates [1]. - The purchase price of US$0.06 per share reflects a premium of 50% over the last trading price [11]. - The proposal is influenced by recent financial liabilities imposed on the company, totaling approximately RMB576.5 million, which have adversely affected its financial condition [10][12]. Group 2: Evaluation Process - The Special Committee of LakeShore Biopharma will evaluate the proposed transaction with the help of financial and legal advisors [2]. - No decisions have been made regarding the proposal or any alternative strategic options [3]. Group 3: Company Background - LakeShore Biopharma is a global biopharmaceutical company focused on developing vaccines and therapeutic biologics for infectious diseases and cancer [4]. - The company operates in China, Singapore, and the Philippines, leveraging a proprietary PIKA® immunomodulating technology platform [4].